2025 年 ASCO 大会正在召开中。本届大会上,阿斯利康有超过 80 个摘要公布,其中包括多款在研新药的研究。双抗作为阿斯利康在研管线的重要布局,本次也有多项研究亮相。本文将分享 Rilvegostomig(PD-1×TIGIT 双抗)、AZD0486(CD19×CD3 双抗)的三项研究数据。Insight 数据显示,阿斯利康尚无双抗药物获批上市。Rilvegostomig、AZD0486 ...
Source Link2025 年 ASCO 大会正在召开中。本届大会上,阿斯利康有超过 80 个摘要公布,其中包括多款在研新药的研究。双抗作为阿斯利康在研管线的重要布局,本次也有多项研究亮相。本文将分享 Rilvegostomig(PD-1×TIGIT 双抗)、AZD0486(CD19×CD3 双抗)的三项研究数据。Insight 数据显示,阿斯利康尚无双抗药物获批上市。Rilvegostomig、AZD0486 ...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.